United States

UroGen Pharma is a biotech company that develops and commercializes solutions for specialty cancers and urothelial diseases. Its products include RTGel, a hydrogel to improve existing drugs, and Jelmyto for pyelocalyceal solution. Its lead product candidate is UGN-102, in Phase III clinical trials for non-muscle invasive urothelial cancer. The company has license agreements with Allergan Pharmaceuticals and Agenus Inc. and a research collaboration with MD Anderson. UroGen Pharma was founded in 2004 and is based in Princeton, New Jersey.

Google

Produk Bestuurder

Data Wetenskaplike

UroGen Pharma

UroGen Pharma Oop Poste

Is jy gereed om jou loopbaan te bevorder? Kyk na hierdie oop posisies by UroGen Pharma.